(NASDAQ: ASND) Ascendis Pharma A's forecast annual revenue growth rate of 45.15% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.35%.
Ascendis Pharma A's revenue in 2026 is $847,214,117.On average, 18 Wall Street analysts forecast ASND's revenue for 2026 to be $86,791,761,168, with the lowest ASND revenue forecast at $76,725,390,000, and the highest ASND revenue forecast at $98,392,640,136. On average, 18 Wall Street analysts forecast ASND's revenue for 2027 to be $125,768,259,288, with the lowest ASND revenue forecast at $99,558,866,064, and the highest ASND revenue forecast at $152,652,835,944.
In 2028, ASND is forecast to generate $157,563,260,904 in revenue, with the lowest revenue forecast at $118,218,480,912 and the highest revenue forecast at $190,401,727,824.